Preanalytical confounding factors in the analysis of cerebrospinal fluid biomarkers for Alzheimer's disease: The issue of diurnal variation

Frontiers in Neurology

Volumn 6, Issue JUN, 2015, Pages

  Cicognola, Claudia ^a   Chiasserini, Davide ^a   Parnetti, Lucilla ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Circadian rhythm; Confounding factors; Diurnal variability

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BIOLOGICAL MARKER; MELATONIN; OREXIN; TAU PROTEIN;

ADSORPTION; AGE; ALZHEIMER DISEASE; ANALYTICAL PARAMETERS; CENTRIFUGATION; CEREBROSPINAL FLUID ANALYSIS; CIRCADIAN RHYTHM; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DISEASE SEVERITY; EARLY DIAGNOSIS; EVAPORATION; FOOD INTAKE; HEMOLYSIS; HUMAN; LUMBAR PUNCTURE; PREANALYTICAL FACTOR; PROTEIN METABOLISM; PROTEIN SECRETION; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SLEEP WAKING CYCLE; STANDARDIZATION; STORAGE; STORAGE TEMPERATURE; STORAGE TIME;

EID: 84936941824     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2015.00143     Document Type: Review

References (67)

1. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 6:734-46. doi:10.1016/S1474-4422(07)70178-3
2. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, et al. Introduction to the recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement (2011) 7:257-62. doi:10.1016/j.jalz.2011.03.004
3. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol (2014) 13:614-29. doi:10.1016/S1474-4422(14)70090-0
4. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol (2010) 6:131-44. doi:10.1038/nrneurol.2010.4
5. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain (2006) 129:3035-41. doi:10.1093/brain/awl269
6. Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S. Added diagnostic value of CSF biomarkers in differential dementia diagnosis. Neurobiol Aging (2010) 31:1867-76. doi:10.1016/j.neurobiolaging.2008.10.017
7. Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De Leenheir E, et al. Amyloid pathology influences abeta1-42 cerebrospinal fluid levels in dementia with lewy bodies. J Alzheimers Dis (2013) 35:137-46. doi:10.3233/JAD-122176
8. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol (2003) 2:605-13. doi:10.1016/S1474-4422(03)00530-1
9. Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, et al. Performance of aß1-40, aß1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis (2012) 29(1):229-38. doi:10.3233/JAD-2011-111349
10. Spies PE, Slats D, Sjögren JM, Kremer BP, Verhey FR, Rikkert MG. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res (2010) 7(5):470-6. doi:10.2174/156720510791383796
11. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 64:343-9. doi:10.1001/archneur.64.3.noc60123
12. Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 9:705-10. doi:10.1038/sj.mp.4001473
13. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, et al. Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 52:1555-62. doi:10.1212/WNL.52.8.1555
14. Smach MA, Charfeddine B, Ben Othman L, Lammouchi T, Dridi H, Nafati S, et al. Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease. Eur Neurol (2009) 62:349-55. doi:10.1159/000241881
15. Vos SJ, Verhey F, Frölich L, Kornhuber J, Wiltfang J, Maier W, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain (2015) 138(Pt 5):1327-38. doi:10.1093/brain/awv029
16. de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, et al. Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry (2011) 82:240-6. doi:10.1136/jnnp.2010.207183
17. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, et al. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology (2012) 78:47-54. doi:10.1212/WNL.0b013e31823ed0f0
18. Brys M, Pirraglia E, Rich K, Rolstad S, Mosconi L, Switalski R, et al. Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment. Neurobiol Aging (2009) 30:682-90. doi:10.1016/j.neurobiolaging.2007.08.010
19. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, et al. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology (2007) 69:631-9. doi:10.1212/01.wnl.0000267428.62582.aa
20. Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, et al. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. Arch Neurol (2009) 66:638-45. doi:10.1001/archneurol.2009.55
21. Meijs AP, Claassen JA, Rikkert MG, Schalk BW, Meulenbroek O, Kessels RP, et al. How does additional diagnostic testing influence the initial diagnosis in patients with cognitive complaints in a memory clinic setting? Age Ageing (2015) 44(1):72-7. doi:10.1093/ageing/afu053
22. Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J. Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J Neural Transm (2009) 116(9):1163-7. doi:10.1007/s00702-009-0277-y
23. Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative. Alzheimers Dement (2014) 10(6):808-17. doi:10.1016/j.jalz.2014.03.003
24. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, et al. CSF biomarker variability in the Alzheimer's association quality control program. Alzheimers Dement (2013) 9(3):251-61. doi:10.1016/j.jalz.2013.01.010
25. Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, et al. The Alzheimer's association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 7:386-95. doi:10.1016/j.jalz.2011.05.2243
26. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology (2009) 73(22):1914-22. doi:10.1212/WNL.0b013e3181c47cc2
27. Plebani M. Errors in clinical laboratories or errors in laboratory medicine? Clin Chem Lab Med (2006) 44:750-9. doi:10.1515/CCLM.2006.123
28. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative. Alzheimers Dement (2012) 8(1):65-73. doi:10.1016/j.jalz.2011.07.004
29. Mollenhauer B, Trautmann E, Otte B, Ng J, Spreer A, Lange P, et al. a-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm (2012) 119(7):739-46. doi:10.1007/s00702-012-0784-0
30. Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med (2012) 6(4):419-30. doi:10.2217/bmm.12.46
31. Berven FS, Kroksveen AC, Berle M, Rajalahti T, Flikka K, Arneberg R, et al. Pre-analytical influence on the low molecular weight cerebrospinal fluid proteome. Proteomics Clin Appl (2007) 1(7):699-711. doi:10.1002/prca.200700126
32. Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsäter H, Anckarsäter R, et al. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alzheimers Dis (2010) 5:2010. doi:10.4061/2010/986310
33. Willemse EA, Koel-Simmelink MJ, Durieux-Lu S, van der Flier WM, Teunissen CE. Standard biobanking conditions prevent evaporation of body fluid samples. Clin Chim Acta (2015) 442:141-5. doi:10.1016/j.cca.2015.01.036
34. Greco V, Pieragostino D, Piras C, Aebersold R, Wiltfang J, Caltagirone C, et al. Direct analytical sample quality assessment for biomarker investigation: qualifying cerebrospinal fluid samples. Proteomics (2014) 14(17-18):1954-62. doi:10.1002/pmic.201300565
35. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, et al. Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem (2005) 51:189-95. doi:10.1373/clinchem.2004.039735
36. Morin LP. Neuroanatomy of the extended circadian rhythm system. Exp Neurol (2013) 243:4-20. doi:10.1016/j.expneurol.2012.06.026
37. Tahara Y, Kuroda H, Saito K, Nakajima Y, Kubo Y, Ohnishi N, et al. In vivo monitoring of peripheral circadian clocks in the mouse. Curr Biol (2012) 22(11):1029-34. doi:10.1016/j.cub.2012.04.009
38. Cho S, Yujnovsky I, Doi M, Sassone-Corsi P. Transplantation of mouse embryo fibroblasts: an approach to study the physiological pathways linking the suprachiasmatic nucleus and peripheral clocks. Methods Enzymol (2005) 393:469-78. doi:10.1016/S0076-6879(05)93023-1
39. Mohawk JA, Green CB, Takahashi JS. Central and peripheral circadian clocks in mammals. Annu Rev Neurosci (2012) 35:445-62. doi:10.1146/annurev-neuro-060909-153128
40. Kaneko M, Kaneko K, Shinsako J, Dallman MF. Adrenal sensitivity to adrenocorticotropin varies diurnally. Endocrinology (1981) 109:70-5. doi:10.1210/endo-109-1-70
41. Arjona A, Silver AC, Walker WE, Fikrig E. Immunity's fourth dimension: approaching the circadian-immune connection. Trends Immunol (2012) 33(12):607-12. doi:10.1016/j.it.2012.08.007
42. Narasimamurthy R, Hatori M, Nayak SK, Liu F, Panda S, Verma IM. Circadian clock protein cryptochrome regulates the expression of proinflammatory cytokines. Proc Natl Acad Sci U S A (2012) 109(31):12662-7. doi:10.1073/pnas.1209965109
43. Harper DG, Stopa EG, McKee AC, Satlin A, Fish D, Volicer L. Dementia severity and Lewy bodies affect circadian rhythms in Alzheimer disease. Neurobiol Aging (2004) 25:771-81. doi:10.1016/j.neurobiolaging.2003.04.009
44. Bianchetti A, Scuratti A, Zanetti O, Binetti G, Frisoni GB, Magni E, et al. Predictors of mortality and institutionalization in Alzheimer disease patients 1 year after discharge from an Alzheimer dementia unit. Dementia (1995) 6:108-12.
45. Videnovic A, Lazar AS, Barker RA, Overeem S. 'The clocks that time us' - circadian rhythms in neurodegenerative disorders. Nat Rev Neurol (2014) 10(12):683-93. doi:10.1038/nrneurol.2014.206
46. Tranah GJ, Blackwell T, Stone KL, Ancoli-Israel S, Paudel ML, Ensrud KE, et al. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol (2011) 70:722-32. doi:10.1002/ana.22468
47. Skene DJ, Swaab DF. Melatonin rhythmicity: effect of age and Alzheimer's disease. Exp Gerontol (2003) 38:199-206. doi:10.1016/S0531-5565(02)00198-5
48. Lin L, Huang QX, Yang SS, Chu J, Wang JZ, Tian Q. Melatonin in Alzheimer's disease. Int J Mol Sci (2013) 14:14575-93. doi:10.3390/ijms140714575
49. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res (2003) 35:125-30. doi:10.1034/j.1600-079X.2003.00065.x
50. Wu YH, Feenstra MG, Zhou JN, Liu RY, Toranõ JS, Van Kan HJ, et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab (2003) 88:5898-906. doi:10.1210/jc.2003-030833
51. Swaab DF, Fliers E, Partiman TS. The suprachiasmatic nucleus of the human brain in relation to sex, age and senile dementia. Brain Res (1985) 342:37-44. doi:10.1016/0006-8993(85)91350-2
52. Wu YH, Zhou JN, Van Heerikhuize J, Jockers R, Swaab DF. Decreased MT1 melatonin receptor expression in the suprachiasmatic nucleus in aging and Alzheimer's disease. Neurobiol Aging (2007) 28:1239-47. doi:10.1016/j.neurobiolaging.2006.06.002
53. Wu YH, Fischer DF, Kalsbeek A, Garidou-Boof ML, van der Vliet J, van Heijningen C, et al. Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock". FASEB J (2006) 20:1874-6. doi:10.1096/fj.05-4446fje
54. Sterniczuk R, Dyck RH, Laferla FM, Antle MC. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 1. Circadian changes. Brain Res (2010) 1348:139-48. doi:10.1016/j.brainres.2010.05.013
55. Ju YE, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology - a bidirectional relationship. Nat Rev Neurol (2014) 10:115-9. doi:10.1038/nrneurol.2013.269
56. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-ß dynamics are regulated by orexin and the sleep-wake cycle. Science (2009) 326:1005-7. doi:10.1126/science.1180962
57. Slats D, Claassen JA, Lammers GJ, Melis RJ, Verbeek MM, Overeem S. Association between hypocretin-1 and amyloid-ß42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls. Curr Alzheimer Res (2012) 9(10):1119-25. doi:10.2174/156720512804142840
58. Slats D, Claassen JA, Verbeek MM, Overeem S. Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: focus on the role of hypocretin and melatonin. Ageing Res Rev (2013) 12(1):188-200. doi:10.1016/j.arr.2012.04.003
59. Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M, Claassen JA. Effect of 1 night of total sleep deprivation on cerebrospinal fluid ß-amyloid 42 in healthy middle-aged men: a randomized clinical trial. JAMA Neurol (2014) 71(8):971-7. doi:10.1001/jamaneurol.2014.1173
60. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology (2007) 68(9):666-9. doi:10.1212/01.wnl.0000256043.50901.e3
61. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 56(6):673-80. doi:10.1001/archneur.56.6.673
62. Slats D, Claassen JA, Spies PE, Borm G, Besse KT, van Aalst W, et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol Aging (2012) 33(4):e1-9. doi:10.1016/j.neurobiolaging.2011.07.008
63. Moghekar A, Goh J, Li M, Albert M, O'Brien RJ. Cerebrospinal fluid Aß and tau level fluctuation in an older clinical cohort. Arch Neurol (2012) 69(2):246-50. doi:10.1001/archneurol.2011.732
64. Spies PE, Verbeek MM, van Groen T, Claassen JA. Reviewing reasons for the decreased CSF Abeta42 concentration in Alzheimer disease. Front Biosci (2012) 17:2024-34. doi:10.2741/4035
65. Dobrowolska JA, Kasten T, Huang Y, Benzinger TL, Sigurdson W, Ovod V, et al. Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system. PLoS One (2014) 9(3):e89998. doi:10.1371/journal.pone.0089998
66. Yamauchi K, Tozuka M, Nakabayashi T, Sugano M, Hidaka H, Kondo Y, et al. Apolipoprotein E in cerebrospinal fluid: relation to phenotype and plasma apolipoprotein E concentrations. Clin Chem (1999) 45(4):497-504.
67. Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim J, Yarasheski KE, et al. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One (2012) 7(6):e38013. doi:10.1371/journal.pone.0038013